Skip to main content
. Author manuscript; available in PMC: 2009 Jan 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2007 Mar 29;61(1):133–144. doi: 10.1007/s00280-007-0458-z

Fig. 4.

Fig. 4

Rapamycin amount remaining to be excreted in urine (ARE) plot (filled square), rate of urinary excretion plot (open square), concentration-time profile in blood (filled circle) and plasma plots (open circle) after IV administration of a) control rapamycin, b) rapamycin in PEG-b-PCL, and c) rapamycin in PEG-b-PCL + α-tocopherol formulation (10 mg/kg) to rats (mean ± SEM, n = 4 per group)